No-shows at Shanghai car expo reflect brutal mainland competition
Hyundai, Hozon, Jaguar Land Rover, Polestar and nearly a dozen other marques miss the world's largest auto event.
Amphenol Q1 Earnings: 48% Topline Growth, Driven By IT, Mobile, Defense Sectors - Amphenol ( NYSE:APH )
Amphenol Q1 sales soar 48% YoY to $4.81B, driven by growth in IT, mobile, defense and acquisitions, beating estimates. Amphenol raises Q2 sales and EPS guidance, expecting up to 50% YoY growth, fueled by strong performance and acquisitions. Markets are messy-but the right setups can still ...
Caro Holdings Launches AI Chat Agent Platform to Revolutionize Customer Service and Boost Business Efficiency
Caro Holdings launches AI Chat Agent platform to help businesses cut costs, boost service, and scale faster - without adding headcount.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Atkore - Atkore ( NYSE:ATKR )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Atkore To Contact Him Directly To Discuss Their Options
Caro Holdings Launches AI Chat Agent Platform to Revolutionize Customer Service and Boost Business Efficiency - Caro Hldgs ( OTC:CAHO )
SHEFFIELD, United Kingdom, April 23, 2025 ( GLOBE NEWSWIRE ) -- Caro Holdings announces the release of its new AI Chat Agent platform - an intelligent, always-on assistant team built to help businesses save time, cut costs, and deliver top-tier customer service without hiring additional staff.
Here's how HEX's Richard Heart beat SEC fraud charges
Richard Heart, the controversial founder of HEX, is claiming total victory over the US SEC after years of court battles.On April 21, the SEC said that it would not amend and refile its fraud case against the former child actor and crypto evangelist.
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Eli Lilly ( NYSE: LLY ) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023.Zepbound's prospects still look bright, but ...


